- Home
- CWD vs OGEN Comparison
CWD vs OGEN Comparison
Compare CWD & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWD
- OGEN
- Stock Information
- Founded
- CWD 2009
- OGEN 1996
- Country
- CWD United States
- OGEN United States
- Employees
- CWD N/A
- OGEN N/A
- Industry
- CWD Real Estate
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- CWD Finance
- OGEN Health Care
- Exchange
- CWD Nasdaq
- OGEN Nasdaq
- Market Cap
- CWD 4.5M
- OGEN 5.4M
- IPO Year
- CWD 2023
- OGEN N/A
- Fundamental
- Price
- CWD $2.42
- OGEN $1.14
- Analyst Decision
- CWD
- OGEN
- Analyst Count
- CWD 0
- OGEN 0
- Target Price
- CWD N/A
- OGEN N/A
- AVG Volume (30 Days)
- CWD 139.2K
- OGEN 52.7K
- Earning Date
- CWD 11-13-2025
- OGEN 11-07-2025
- Dividend Yield
- CWD N/A
- OGEN N/A
- EPS Growth
- CWD N/A
- OGEN N/A
- EPS
- CWD N/A
- OGEN N/A
- Revenue
- CWD $24,657,000.00
- OGEN N/A
- Revenue This Year
- CWD N/A
- OGEN N/A
- Revenue Next Year
- CWD $56.47
- OGEN N/A
- P/E Ratio
- CWD N/A
- OGEN N/A
- Revenue Growth
- CWD N/A
- OGEN N/A
- 52 Week Low
- CWD $1.63
- OGEN $1.01
- 52 Week High
- CWD $48.00
- OGEN $18.90
- Technical
- Relative Strength Index (RSI)
- CWD 29.38
- OGEN 39.04
- Support Level
- CWD $2.82
- OGEN $1.06
- Resistance Level
- CWD $3.09
- OGEN $1.22
- Average True Range (ATR)
- CWD 0.21
- OGEN 0.06
- MACD
- CWD 0.02
- OGEN -0.01
- Stochastic Oscillator
- CWD 1.67
- OGEN 21.43
About CWD CaliberCos Inc.
CaliberCos Inc is an asset management firm whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. The majority of revenue is derived from the fund management fees segment.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.